What's Going On With Actinium Pharmaceuticals Stock?

Actinium Pharmaceuticals Inc ATNM shares are trading higher Tuesday after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or refractory acute myeloid leukemia.

What Happened: Over the weekend, Actinum said Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission with high statistical significance. 22% of patients achieved dCR in the Iomab-B arm compared to zero in the control arm.

Additionally, Iomab-B produced a significant and clinically meaningful improvement in the secondary endpoint of Event-Free Survival, with a 78% reduction in the probability of an event.

Actinium presented the full results Saturday evening at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood & Marrow Transplant Research.

Following the presentation, HC Wainwright & Co reiterated Actinium with a Buy and maintained a $53 price target and William Blair downgraded Actinium from Outperform to Market Perform.

See Also: Why BioCryst Pharmaceuticals Stock Is Sliding Today

ATNM Price Action: Actinium shares surged higher in early premarket trading before pulling back.

The stock was up 7.56% at $14.80 at time of publication, according to Benzinga Pro.

Photo: StockSnap from Pixabay.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!